Puma Biotechnology (PBYI) Restructuring Costs (2012)

Puma Biotechnology (PBYI) posted Restructuring Costs of $12.0 million for Q4 2012, up 84.62% on a QoQ basis from $6.5 million in Q3 2012.

Puma Biotechnology (PBYI) Restructuring Costs (2012) Analysis & Trends

Puma Biotechnology's Restructuring Costs history runs 1 years deep, the most recent figure standing at $12.0 million for Q4 2012.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	67,072.09 Bn	67,072.09 Bn	-
2	Nanobiotix	1,894.61 Bn	1,894.55 Bn	-
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-
4	BeOne Medicines	471.64 Bn	466.85 Bn	1.35 Bn
5	Vertex Pharmaceuticals	121.72 Bn	114.47 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	68.28 Bn	59.52 Bn	3.31 Bn
7	Belite Bio	61.40 Bn	61.40 Bn	-
8	Argenx Se	56.94 Bn	56.94 Bn	1.18 Bn
9	Revolution Medicines	37.37 Bn	37.37 Bn	-
10	Puma Biotechnology	406.51 Mn	368.22 Mn	34.39 Mn

Download Data